Abstract
Pentamidine pulmonary pharmacokinetics were studied in 13 patients receiving once-daily inhaled therapy and 4 patients receiving low-dose intravenous treatment for Pneumocystis carinii pneumonia. Twenty-four hours after inhaled or intravenous therapy, the mean (+/- standard deviation) concentrations of pentamidine in serial bronchoalveolar specimen fluid ranged from 28.6 +/- 10 to 177.5 +/- 28 ng/ml and 6.05 +/- 2.29 to 21.4 +/- 15.7 ng/ml, respectively. Pentamidine concentrations in brochoalveolar fluid were generally higher after 2 weeks than after day 1 of therapy; however, the differences were not statistically different (P greater than 0.05). The pulmonary half-life after inhaled therapy is long; pentamidine was detectable in bronchoalveolar fluid at 33 (one patient), 69 (one patient), and 115 (one patient) days following the completion of 2 weeks of therapy. Systemic absorption of pentamidine was minimal; the mean (+/- standard deviation) plasma concentration at the completion of inhalation was 13.84 +/- 11.8 ng/ml, or 5% of the mean peak plasma concentration achieved after intravenous administration. Accumulation in the plasma did not occur with repeated inhalation as has been described with multiple intravenous dosing. Cumulative urinary excretion 24 h after the first dose was 5% of that observed with intravenous administration. These data may have importance in designing dosage regimens for the further investigation of inhaled pentamidine for treatment or prophylaxis of P. carinii pneumonia.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Conte J. E., Jr, Hollander H., Golden J. A. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. A pilot study. Ann Intern Med. 1987 Oct;107(4):495–498. doi: 10.7326/0003-4819-107-4-495. [DOI] [PubMed] [Google Scholar]
- Conte J. E., Jr, Upton R. A., Lin E. T. Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. J Infect Dis. 1987 Dec;156(6):885–890. doi: 10.1093/infdis/156.6.885. [DOI] [PubMed] [Google Scholar]
- Conte J. E., Jr, Upton R. A., Phelps R. T., Wofsy C. B., Zurlinden E., Lin E. T. Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis. 1986 Dec;154(6):923–929. doi: 10.1093/infdis/154.6.923. [DOI] [PubMed] [Google Scholar]
- Debs R. J., Straubinger R. M., Brunette E. N., Lin J. M., Lin E. J., Montgomery A. B., Friend D. S., Papahadjopoulos D. P. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. Am Rev Respir Dis. 1987 Mar;135(3):731–737. doi: 10.1164/arrd.1987.135.3.731. [DOI] [PubMed] [Google Scholar]
- Golden J. A., Hollander H., Stulbarg M. S., Gamsu G. Bronchoalveolar lavage as the exclusive diagnostic modality for Pneumocystis carinii pneumonia. A prospective study among patients with acquired immunodeficiency syndrome. Chest. 1986 Jul;90(1):18–22. doi: 10.1378/chest.90.1.18. [DOI] [PubMed] [Google Scholar]
- Montgomery A. B., Debs R. J., Luce J. M., Corkery K. J., Turner J., Brunette E. N., Lin E. T., Hopewell P. C. Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet. 1987 Aug 29;2(8557):480–483. doi: 10.1016/s0140-6736(87)91794-6. [DOI] [PubMed] [Google Scholar]
- Sirr S. A., Juenemann P. J., Tom H., Boudreau R. J., Chandler R. P., Loken M. K. Effect of ethanol on droplet size, efficiency of delivery, and clearance characteristics of technetium-99m DTPA aerosol. J Nucl Med. 1985 Jun;26(6):643–646. [PubMed] [Google Scholar]